What is claimed is:

1. A tasted-masked pharmaceutical composition comprising a water suspendable co-granulate of immediate release microcapsules and at least one inactive ingredient, wherein said microcapsules comprise fexofenadine and a water-insoluble polymer coating.

2. The pharmaceutical composition of claim **1**, wherein said fexofenadine is crystalline fexofenadine.

3. The pharmaceutical composition of claim **1**, wherein said fexofenadine is fexofenadine hydrochloride.

4. The pharmaceutical composition of claim **1**, wherein said water-insoluble polymer is selected from the group consisting of ethylcellulose, polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, ammonio-methacrylate copolymers and mixtures thereof.

5. The pharmaceutical composition of claim **4**, wherein said water-insoluble polymer is ethylcellulose.

6. The pharmaceutical composition of claim **1**, wherein the weight of the water insoluble polymer of said microcapsules is from about 2% to about 40%.

7. The pharmaceutical composition of claim **6**, the weight of the water insoluble polymer of said microcapsules is from about 10% to about 20%.

8. The pharmaceutical composition of claim **7**, wherein the weight of the water insoluble polymer of said microcapsules is from about 13% to about 18%.

9. The pharmaceutical composition of claim **3**, wherein said composition releases at least about 60% of said fexofenadine hydrochloride within 15 minutes in pH 6.8 JP 2°nd fluid.

10. The pharmaceutical composition of claim **9**, wherein said composition releases at least about 80% of said fexofenadine hydrochloride within 15 minutes in pH 6.8 JP 2°nd fluid.

11. The pharmaceutical composition of claim **10**, wherein said composition releases at least about 90% of said fexofenadine hydrochloride within 15 minutes in pH 6.8 JP 2°nd fluid.

12. The pharmaceutical composition of claim **11**, wherein said composition releases at least about 95% of said fexofenadine hydrochloride within 15 minutes in pH 6.8 JP 2°nd fluid.

13. The pharmaceutical composition of claim **1**, wherein said microcapsules further comprise a surfactant.

14. The pharmaceutical composition of claim **13**, wherein said microcapsules further comprise a glidant or an antisticking agent.

15. The pharmaceutical composition of claim **13**, wherein said surfactant is selected from the group consisting of sodium docusate, sorbitan oleate, sorbitan laurate and sodium lauryl sulfate.

16. The pharmaceutical composition of claim **15**, wherein said surfactant is sodium docusate.

17. The pharmaceutical composition of claim **1**, further comprising additional inactive ingredients which are optionally granulated and/or at least one excipient.

18. The pharmaceutical composition of claim **17**, wherein said inactive ingredient is selected from the group consisting of sugar alcohol saccharide, granulated sugar alcohol, and granulated saccharide.

19. The pharmaceutical composition of claim **17**, wherein said inactive ingredient is sucrose, xanthan gum, cyclodextrin, and mixtures thereof.

20. The pharmaceutical composition of claim **1**, wherein said composition is in the form of a tablet, capsule or sachet.

21. The pharmaceutical composition of claim **1**, wherein the co-granule consists of taste masked immediate release microcapsules, xanthan gum and sucrose, wherein the weight ratio of microcapsules to the (xanthan gum+sucrose) is 1:7.

22. The pharmaceutical composition of claim **17** wherein the ratio of the co-granulated microcapsules to the granulated inactive ingredient is 1:1.

23. The pharmaceutical composition of claims **21**-**22** wherein said composition is in the form of sachet.

24. A process for preparing the pharmaceutical composition of claim **1**, wherein the pharmaceutical composition comprises taste-masked immediate release microcapsules comprising fexofenadine coated with a water-insoluble polymer, wherein said process comprises the steps of: (a) dissolving a water-insoluble polymer in an organic solvent; (b) suspending fexofenadine in said organic solvent; (c) applying a coating of said water-insoluble polymer onto said fexofenadine by phase separation; and (d) separating said microcapsules from said organic solvent; (e) optional wetting of microcapsules; (f) co-granulating the microcapsules with at least one inactive ingredient; (g) separately optionally granulating at least one inactive ingredient; and (h) mixing of co-granulate obtained in step (f) together with the granulated inactive ingredient obtained in step (g).

25. The process of claim **24**, wherein said fexofenadine is crystalline fexofenadine.

26. The process of claim **24**, wherein said fexofenadine is fexofenadine hydrochloride.

27. The process of claim **26**, further comprising the step of drying said separated microcapsules after step (d).

28. The process of claim **27**, further comprising the step of adding a phase inducer agent to said organic solvent to promote step (c).

29. The process of claim **28**, wherein said phase inducer agent is selected from the group consisting of polyethylene, polyisobutylene, butyl rubber, polybutadiene, organosilicon polymers, and paraffin.

30. The process of claim **29**, wherein said phase inducer agent is polyethylene.

31. A process for preparing a taste-masked immediate release pharmaceutical composition in form of sachets comprising the following steps: (a) dissolving a water-insoluble polymer in an organic solvent; (b) suspending fexofenadine in said organic solvent; (c) applying a coating of said water-insoluble polymer onto said fexofenadine by phase separation; (d) separating said microcapsules from said organic solvent; (e) optional wetting of microcapsules; (f) co-granulating the microcapsules with at least one inactive ingredient; (g) separately granulating at least one inactive ingredient; (h) mixing of co-granulate obtained in step (f) together with the granulated inactive ingredient obtained in step (g); (i) filling the bulk mixture of step (h) in sachets.

32. A method for treating an inflammation related condition in an individual comprising administering to an individual in need thereof a pharmaceutical composition comprising taste-masked immediate release microcapsules or taste masked immediate release co-granulated microcapsules, wherein said microcapsules comprise fexofenadine and a water-insoluble polymer coating.

33. The method of claim **32**, wherein said fexofenadine is crystalline fexofenadine.

34. The method of claims **32-33**, wherein said fexofenadine is fexofenadine hydrochloride.

35. The method of claim **32**, wherein the weight of the water insoluble polymer of said microcapsules is from about 2% to about 40%.

36. The method of claim **34**, wherein the weight of the water insoluble polymer of said microcapsules is from about 10% to about 20%.

37. The method of claim **36**, wherein the weight of the water insoluble polymer of said microcapsules is from about 13% to about 18%.

38. The method of claim **32**, wherein said inflammation related condition is seasonal allergic rhinitis or chronic idiopathic urticaria.

39. The method of claim **38**, wherein said inflammation related condition is seasonal allergic rhinitis.

40. The method of claim **38**, wherein said inflammation related condition is chronic idiopathic

urticaria.

41. The method of claim **32**, wherein said water-insoluble polymer is selected from the group consisting of ethylcellulose, polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, ammonio-methacrylate copolymers and mixtures thereof.

42. The method of claim **41**, wherein said water-insoluble polymer is ethylcellulose.

43. The method of claim **32**, wherein said composition releases at least about 80% of said fexofenadine hydrochloride within 15 minutes in pH 6.8 JP 2°nd fluid.

44. The method of claim **43**, wherein said composition releases at least about 90% of said fexofenadine hydrochloride within 15 minutes in pH 6.8 JP 2°nd fluid.

45. The method of claim **32**, wherein said microcapsules further comprise a surfactant.

46. The method of claim **44**, wherein said microcapsules further comprise a glidant or an antisticking agent.

47. The method of claim **45**, wherein said surfactant is selected from the group consisting of sodium docusate, sorbitan oleate, sorbitan laurate and sodium lauryl sulfate.

48. The method of claim **47**, wherein said surfactant is sodium docusate.

49. The method of claim **32**, wherein said pharmaceutical composition further comprises at least one inactive ingredient which is optionally granulated and/or at least one excipient.

50. The method of claim **49**, wherein said inactive ingredient is selected from the group consisting of sugar alcohol, saccharide, granulated sugar alcohol, and granulated saccharide.

51. The method of claim **50**, wherein said inactive ingredient is sucrose, xanthan gum, cyclodextrin, and mixtures thereof.

52. The method of claim **32**, wherein said pharmaceutical composition is in the form of a tablet, capsule or sachet.

53. The method of claim **52**, wherein said pharmaceutical composition is in the form of a sachet.